Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting T cell PCIF1 for antitumor immunity

BC Staff
April 1, 2025 3:41 AM UTC

Inhibiting PCIF1 – an RNA M6Am methyltransferase that promotes terminal modification of mRNA caps to decrease gene expression – in CD8+ T cells could help treat cancer by increasing the activation and ferroptosis resistance of tumor-targeting T cells.

In bioinformatic analyses of public B cell malignancy and melanoma patient datasets, higher PCIF1 mRNA expression in tumor-infiltrating CD8+ T cells correlated with decreased response to CAR T cell therapy and immune checkpoint therapy, respectively. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Peking University

Wuhan University